SonoMotion

SonoMotion is a private medical device company pioneering office-based, non-invasive treatments for kidney stone disease. Its platform, featuring the FDA-cleared Break Wave lithotripsy device and the Stone Clear fragment repositioning system, targets a significant procedural market by eliminating the need for general anesthesia and operating room settings. Backed by over $38 million in funding and key regulatory milestones like FDA Breakthrough Device designation, the company is positioned to disrupt the standard of care for a highly prevalent condition.

Ultrasound-based platform utilizing low-pressure waves for non-invasive kidney stone fragmentation (Break Wave) and fragment repositioning (Stone Clear).

SonoMotion competes in the kidney stone management market dominated by large players like Boston Scientific (lithotripters, ureteroscopes), Olympus, and Stryker. Its primary competitive differentiation is the office-based, anesthesia-free approach, competing against traditional shock wave lithotripsy (SWL) and ureteroscopy procedures that typically require an OR or hospital setting. Other companies are also exploring novel lithotripsy technologies, such as acoustic and laser-based systems.